Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing three active ingredients: Dingkundan, ethinylestradiol, and cyproterone acetate. Ethinylestradiol is a synthetic estrogen, and cyproterone acetate is a synthetic progestogen with anti-androgenic properties. The combination of ethinylestradiol and cyproterone acetate is widely used to treat androgen-dependent conditions in women such as severe acne, seborrhea (oily skin), hirsutism (excessive hair growth), and sometimes for contraception in women who require treatment for these conditions[1][3][4][5][6][7]. Cyproterone acetate acts by blocking androgen receptors and suppressing ovarian androgen production, while ethinylestradiol increases sex hormone–binding globulin to reduce free circulating androgens[5]. Dingkundan appears to be an additional component; however, there is no widely recognized pharmaceutical or clinical information about "Dingkundan" as an established drug or supplement in major international databases. Therefore, the mechanism of action or therapeutic role of Dingkundan within this combination cannot be determined from available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dingkundan + ethinylestradiol + cyproterone acetate.